Global Blood Therapeutics Stock Forecast, Price & News

Global Blood Therapeutics (NASDAQ:GBT) Frequently Asked Questions

Is Global Blood Therapeutics a buy right now?

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Global Blood Therapeutics in the last year. There are currently 6 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Global Blood Therapeutics stock.
View analyst ratings for Global Blood Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Global Blood Therapeutics?

Wall Street analysts have given Global Blood Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Global Blood Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Global Blood Therapeutics' next earnings date?

Global Blood Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Global Blood Therapeutics.

How were Global Blood Therapeutics' earnings last quarter?

Global Blood Therapeutics, Inc. (NASDAQ:GBT) issued its quarterly earnings results on Monday, August, 2nd. The company reported ($1.12) earnings per share for the quarter, topping the consensus estimate of ($1.19) by $0.07. The business earned $47.56 million during the quarter, compared to analysts' expectations of $43.87 million. Global Blood Therapeutics had a negative net margin of 161.55% and a negative trailing twelve-month return on equity of 68.58%.
View Global Blood Therapeutics' earnings history.

How has Global Blood Therapeutics' stock been impacted by COVID-19?

Global Blood Therapeutics' stock was trading at $54.85 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, GBT shares have decreased by 51.6% and is now trading at $26.55.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for GBT?

18 analysts have issued 1 year target prices for Global Blood Therapeutics' stock. Their forecasts range from $36.00 to $124.00. On average, they expect Global Blood Therapeutics' share price to reach $70.73 in the next twelve months. This suggests a possible upside of 166.4% from the stock's current price.
View analysts' price targets for Global Blood Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Global Blood Therapeutics' key executives?

Global Blood Therapeutics' management team includes the following people:

• Ted W. Love, President, Chief Executive Officer & Director
• Nazila Habibizad, Senior Vice President-Operations
• Jeffrey S. Farrow, Chief Financial & Accounting Officer
• Kim Smith-Whitley, Executive VP, Head-Research & Development
• Jung E. Choi, Chief Business & Strategy Officer

What is Ted W. Love, M.D.'s approval rating as Global Blood Therapeutics' CEO?

13 employees have rated Global Blood Therapeutics CEO Ted W. Love, M.D. on Glassdoor.com. Ted W. Love, M.D. has an approval rating of 100% among Global Blood Therapeutics' employees. This puts Ted W. Love, M.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Global Blood Therapeutics' key competitors?

Some companies that are related to Global Blood Therapeutics include Arrowhead Pharmaceuticals (ARWR), HUTCHMED (HCM), Blueprint Medicines (BPMC), Ultragenyx Pharmaceutical (RARE), Perrigo (PRGO), Allakos (ALLK), Mawson Infrastructure Group (WIZP), I-Mab (IMAB), Alkermes (ALKS), Ionis Pharmaceuticals (IONS), TG Therapeutics (TGTX), Cerevel Therapeutics (CERE), Arvinas (ARVN), Schrödinger (SDGR) and Reata Pharmaceuticals (RETA).
View all of GBT's competitors.

What other stocks do shareholders of Global Blood Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Global Blood Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Exelixis (EXEL), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), Advanced Micro Devices (AMD), Gilead Sciences (GILD) and Square (SQ).

When did Global Blood Therapeutics IPO?

(GBT) raised $102 million in an initial public offering on Wednesday, August 12th 2015. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.

What is Global Blood Therapeutics' stock symbol?

Global Blood Therapeutics trades on the NASDAQ under the ticker symbol "GBT."

Who are Global Blood Therapeutics' major shareholders?

Global Blood Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Bank of America Corp DE (9.83%), Bank of America Corp DE (9.83%), Vanguard Group Inc. (9.39%), BlackRock Inc. (9.25%), Perceptive Advisors LLC (6.65%) and Perceptive Advisors LLC (6.65%). Company insiders that own Global Blood Therapeutics stock include Dawn Svoronos, De Dominicis Robert, Deval L Patrick, Eric Fink, Jeffrey S Farrow, Joshua Lehrer-Graiwer, Lesley Ann Calhoun, Mark L Perry, Philip A Pizzo, Scott W Morrison, Ted W Love, Tricia Borga Suvari and Willie L Jr Brown.
View institutional ownership trends for Global Blood Therapeutics.

Which major investors are selling Global Blood Therapeutics stock?

GBT stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Perceptive Advisors LLC, Perceptive Advisors LLC, JPMorgan Chase & Co., Frontier Capital Management Co. LLC, Nuveen Asset Management LLC, Susquehanna International Group LLP, and Price T Rowe Associates Inc. MD. Company insiders that have sold Global Blood Therapeutics company stock in the last year include Eric Fink, Philip A Pizzo, and Scott W Morrison.
View insider buying and selling activity for Global Blood Therapeutics or view top insider-selling stocks.

Which major investors are buying Global Blood Therapeutics stock?

GBT stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Morgan Stanley, Morgan Stanley, Northern Trust Corp, Geode Capital Management LLC, Yiheng Capital Management L.P., and Vanguard Group Inc.. Company insiders that have bought Global Blood Therapeutics stock in the last two years include Eric Fink, and Willie L Jr Brown.
View insider buying and selling activity for Global Blood Therapeutics or or view top insider-buying stocks.

How do I buy shares of Global Blood Therapeutics?

Shares of GBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Global Blood Therapeutics' stock price today?

One share of GBT stock can currently be purchased for approximately $26.55.

How much money does Global Blood Therapeutics make?

Global Blood Therapeutics has a market capitalization of $1.66 billion and generates $123.80 million in revenue each year. The company earns $-247,550,000.00 in net income (profit) each year or ($4.04) on an earnings per share basis.

How many employees does Global Blood Therapeutics have?

Global Blood Therapeutics employs 389 workers across the globe.

What is Global Blood Therapeutics' official website?

The official website for Global Blood Therapeutics is www.gbt.com.

Where are Global Blood Therapeutics' headquarters?

Global Blood Therapeutics is headquartered at 171 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080.

How can I contact Global Blood Therapeutics?

Global Blood Therapeutics' mailing address is 171 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (650) 741-7700 or via email at [email protected].